81102-44-5

Usage

Family

Belongs to the adenosine family

Structure

Modified form of adenosine with a bromine atom at the 8th position and an amino group at the 2nd position of the adenine ring

Potency

Potent and selective agonist for the adenosine A1 receptor

Role

Regulates physiological processes including cardiac function and neurotransmitter release

Therapeutic potential

Studied for potential applications in cardiovascular diseases and neurodegenerative disorders

Target

Specifically targets the adenosine A1 receptor

Candidate

Promising candidate for the development of novel drug treatments

Upstream product

• 2096-10-8 adenosine-2-amine 
• 52921-40-1 9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-2,6-diaminopurine 
• 16321-99-6 2-amino-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine 
• 118-00-3 G 
• 79999-39-6 2',3',5'-tri-O-acetyl-2-chloroadenosine 
• 6979-94-8 2',3',5'-tri-O-acetyl-guanosine 
• 79999-42-1 2-amino-6-azido-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-purine 

Downstream Products

• 4546-70-7 2-amino-2'-deoxyadenosine 
• 81102-46-7 2,6-diamino-8-bromo-9-(2'-O-tosyl-β-D-ribufuranosyl)-purine 

Relevant academic research and scientific papers

Synthesis of Phosphoramidite Monomers Equipped with Complementary Bases for Solid-Phase DNA Oligomerization

We describe the preparation of two monomers that bear complementary nucleobases at the edges (guanine-2′-deoxycytidine and 2-aminoadenine-2′-deoxyuridine) and that are conveniently protected and activated for solid-phase automated DNA synthesis. We report the optimized synthetic routes leading to the four nucleobase derivatives involved, their cross-coupling reactions into dinucleobase-containing monomers, and their oligomerization in the DNA synthesizer.

On the syntheses of 8-heteroaryl-substituted 9-(β-D-ribofuranosyl)-2,6-diaminopurines through Pd-catalyzed coupling in the presence of cupric oxide

Convenient methods for the preparation of 9-(β-D-ribofuranosyl) derivatives of 8-(2- and 3-thienyl)-2,6-diaminopurine and of 8-(2- and 3-furyl)-2,6-diaminopurine, which are potential antiviral agents has been worked out. The key step was a Pd(0)-catalyzed Stille coupling between 2- and 3-tributylstannylthiophene and 2- and 3-tributylstannylfuran and trimethylsilyl protected 9-(β-D-ribofuranosyl)-2,6-diamino-8-bromopurine. The use of N,N-dimethylformamide as solvent at 110° and dichloro(diphenylphosphine-propane)palladium(II) [PdCl2(dppp)] with cupric oxide as co-reagent was essential in order to obtain a fast reaction and high yields.